Matthew T Wheeler Iii

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1783055/publications.pdf

Version: 2024-02-01

101 papers	8,935 citations	81900 39 h-index	45317 90 g-index
109 all docs	109 docs citations	109 times ranked	14191 citing authors

#	Article	IF	Citations
1	The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nature Immunology, 2004, 5, 1052-1060.	14.5	1,016
2	Clinical assessment incorporating a personal genome. Lancet, The, 2010, 375, 1525-1535.	13.7	637
3	Abnormal Calcium Handling Properties Underlie Familial Hypertrophic Cardiomyopathy Pathology in Patient-Specific Induced Pluripotent Stem Cells. Cell Stem Cell, 2013, 12, 101-113.	11.1	584
4	Expansion of the Human Phenotype Ontology (HPO) knowledge base and resources. Nucleic Acids Research, 2019, 47, D1018-D1027.	14.5	539
5	Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2020, 396, 759-769.	13.7	481
6	Accuracy in Wrist-Worn, Sensor-Based Measurements of Heart Rate and Energy Expenditure in a Diverse Cohort. Journal of Personalized Medicine, 2017, 7, 3.	2.5	420
7	Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA - Journal of the American Medical Association, 2014, 311, 1035.	7.4	398
8	Effect of Genetic Diagnosis on Patients with Previously Undiagnosed Disease. New England Journal of Medicine, 2018, 379, 2131-2139.	27.0	261
9	Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts. Nature Medicine, 2019, 25, 911-919.	30.7	221
10	Cost-Effectiveness of Preparticipation Screening for Prevention of Sudden Cardiac Death in Young Athletes. Annals of Internal Medicine, 2010, 152, 276.	3.9	211
11	Challenges in the clinical application of whole-genome sequencing. Lancet, The, 2010, 375, 1749-1751.	13.7	207
12	Interpretation of the Electrocardiogram of Young Athletes. Circulation, 2011, 124, 746-757.	1.6	204
13	A public resource facilitating clinical use of genomes. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 11920-11927.	7.1	194
14	Long-read genome sequencing identifies causal structural variation in a Mendelian disease. Genetics in Medicine, 2018, 20, 159-163.	2.4	189
15	MARRVEL: Integration of Human and Model Organism Genetic Resources to Facilitate Functional Annotation of the Human Genome. American Journal of Human Genetics, 2017, 100, 843-853.	6.2	181
16	Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 KATP channels. Journal of Clinical Investigation, 2002, 110, 203-208.	8.2	173
17	Effect of Moderate-Intensity Exercise Training on Peak Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. JAMA - Journal of the American Medical Association, 2017, 317, 1349.	7.4	160
18	Molecular Transducers of Physical Activity Consortium (MoTrPAC): Mapping the Dynamic Responses to Exercise. Cell, 2020, 181, 1464-1474.	28.9	147

#	Article	IF	Citations
19	The Undiagnosed Diseases Network: Accelerating Discovery about Health and Disease. American Journal of Human Genetics, 2017, 100, 185-192.	6.2	142
20	Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence. PLoS Genetics, 2011, 7, e1002280.	3.5	137
21	Episodic coronary artery vasospasm and hypertension develop in the absence of Sur2 KATP channels. Journal of Clinical Investigation, 2002, 110, 203-208.	8.2	129
22	Medical implications of technical accuracy in genome sequencing. Genome Medicine, 2016, 8, 24.	8.2	123
23	Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy. Circulation: Heart Failure, 2019, 12, e005371.	3.9	96
24	Gene Coexpression Network Topology of Cardiac Development, Hypertrophy, and Failure. Circulation: Cardiovascular Genetics, 2011, 4, 26-35.	5.1	88
25	Physical Activity and Other Health Behaviors in Adults With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2013, 111, 1034-1039.	1.6	86
26	zeta-Sarcoglycan, a novel component of the sarcoglycan complex, is reduced in muscular dystrophy. Human Molecular Genetics, 2002, 11, 2147-2154.	2.9	82
27	Addition of the Electrocardiogram to the Preparticipation Examination of College Athletes. Clinical Journal of Sport Medicine, 2010, 20, 98-105.	1.8	79
28	DNA Sequencing. Circulation, 2012, 125, 931-944.	1.6	72
29	ClinPhen extracts and prioritizes patient phenotypes directly from medical records to expedite genetic disease diagnosis. Genetics in Medicine, 2019, 21, 1585-1593.	2.4	67
30	Smooth muscle cellâ€“extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. Journal of Clinical Investigation, 2004, 113, 668-675.	8.2	64
31	Accuracy of Smartphone Camera Applications for Detecting Atrial Fibrillation. JAMA Network Open, 2020, 3, e202064.	5.9	62
32	A comprehensive iterative approach is highly effective in diagnosing individuals who are exome negative. Genetics in Medicine, 2019, 21, 161-172.	2.4	60
33	Biallelic Mutations in ATP5F1D, which Encodes a Subunit of ATP Synthase, Cause a Metabolic Disorder. American Journal of Human Genetics, 2018, 102, 494-504.	6.2	59
34	Targeting ferroptosis: A novel therapeutic strategy for the treatment of mitochondrial disease-related epilepsy. PLoS ONE, 2019, 14, e0214250.	2.5	59
35	Personalized Preventive Medicine: Genetics and the Response to Regular Exercise in Preventive Interventions. Progress in Cardiovascular Diseases, 2015, 57, 337-346.	3.1	57
36	The effect of digital physical activity interventions on daily step count: a randomised controlled crossover substudy of the MyHeart Counts Cardiovascular Health Study. The Lancet Digital Health, 2019, 1, e344-e352.	12.3	52

#	Article	IF	Citations
37	Overexpression of Î³-Sarcoglycan Induces Severe Muscular Dystrophy. Journal of Biological Chemistry, 2001, 276, 21785-21790.	3.4	51
38	Valsartan in early-stage hypertrophic cardiomyopathy: a randomized phase 2 trial. Nature Medicine, 2021, 27, 1818-1824.	30.7	51
39	Time trajectories in the transcriptomic response to exercise - a meta-analysis. Nature Communications, 2021, 12, 3471.	12.8	48
40	Outcomes in Patients With Cardiac Amyloidosis Undergoing Heart Transplantation. JACC: Heart Failure, 2020, 8, 461-468.	4.1	46
41	Yield of whole exome sequencing in undiagnosed patients facing insurance coverage barriers to genetic testing. Journal of Genetic Counseling, 2019, 28, 1107-1118.	1.6	42
42	Identification of rare and common regulatory variants in pluripotent cells using population-scale transcriptomics. Nature Genetics, 2021, 53, 313-321.	21.4	42
43	Characterization of HNRNPA1 mutations defines diversity in pathogenic mechanisms and clinical presentation. JCI Insight, 2021, 6, .	5.0	38
44	De novo EIF2AK1 and EIF2AK2 Variants Are Associated with Developmental Delay, Leukoencephalopathy, and Neurologic Decompensation. American Journal of Human Genetics, 2020, 106, 570-583.	6.2	37
45	Smooth muscle cellâ€“extrinsic vascular spasm arises from cardiomyocyte degeneration in sarcoglycan-deficient cardiomyopathy. Journal of Clinical Investigation, 2004, 113, 668-675.	8.2	37
46	Sarcoglycans in Vascular Smooth and Striated Muscle. Trends in Cardiovascular Medicine, 2003, 13, 238-243.	4.9	34
47	Secondary Coronary Artery Vasospasm Promotes Cardiomyopathy Progression. American Journal of Pathology, 2004, 164, 1063-1071.	3.8	34
48	Mechanisms of exercise intolerance in patients with hypertrophic cardiomyopathy. American Heart Journal, 2009, 158, e27-e34.	2.7	32
49	Functional nitric oxide synthase mislocalization in cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2004, 36, 213-223.	1.9	31
50	Systems Genomics Identifies a Key Role forÂHypocretin/Orexin Receptor-2 in Human Heart Failure. Journal of the American College of Cardiology, 2015, 66, 2522-2533.	2.8	31
51	Exercise restrictions trigger psychological difficulty in active and athletic adults with hypertrophic cardiomyopathy. Open Heart, 2016, 3, e000488.	2.3	29
52	Silencing of MYH7 ameliorates disease phenotypes in human iPSC-cardiomyocytes. Physiological Genomics, 2020, 52, 293-303.	2.3	29
53	Prevalence and Cumulative Risk of Familial Idiopathic Dilated Cardiomyopathy. JAMA - Journal of the American Medical Association, 2022, 327, 454.	7.4	28
54	Cytoskeletal defects in cardiomyopathy. Journal of Molecular and Cellular Cardiology, 2003, 35, 231-241.	1.9	26

#	Article	IF	Citations
55	Sports genetics moving forward: lessons learned from medical research. Physiological Genomics, 2016, 48, 175-182.	2.3	26
56	Allele-Specific Silencing Ameliorates Restrictive Cardiomyopathy Attributable to a Human Myosin Regulatory Light Chain Mutation. Circulation, 2019, 140, 765-778.	1.6	26
57	The genetics of human performance. Nature Reviews Genetics, 2022, 23, 40-54.	16.3	25
58	Pathologic gene network rewiring implicates PPP1R3A as a central regulator in pressure overload heart failure. Nature Communications, 2019, 10, 2760.	12.8	22
59	Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. FASEB Journal, 2002, 16, 1096-1098.	0.5	21
60	Skeletal Muscle Structure and Function. , 2006, , 674-681.		20
61	Systematic Comparison of Digital Electrocardiograms From Healthy Athletes and Patients With Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 2462-2463.	2.8	20
62	Extracutaneous manifestations in phacomatosis cesioflammea and cesiomarmorata: Case series and literature review. American Journal of Medical Genetics, Part A, 2019, 179, 966-977.	1.2	20
63	Functional and structural analysis of cytokine-selective IL6ST defects that cause recessive hyper-IgE syndrome. Journal of Allergy and Clinical Immunology, 2021, 148, 585-598.	2.9	20
64	Perceived utility and disutility of genomic sequencing for pediatric patients: Perspectives from parents with diverse sociodemographic characteristics. American Journal of Medical Genetics, Part A, 2022, 188, 1088-1101.	1.2	20
65	Cardiomyopathy in animal models of muscular dystrophy. Current Opinion in Cardiology, 2001, 16, 211-217.	1.8	19
66	â€œIt seems like COVID-19 now is the only disease present on Earthâ€• living with a rare or undiagnosed disease during the COVID-19 pandemic. Genetics in Medicine, 2021, 23, 837-844.	2.4	19
67	Clinical sites of the Undiagnosed Diseases Network: unique contributions to genomic medicine and science. Genetics in Medicine, 2021, 23, 259-271.	2.4	18
68	Computerized Q wave dimensions in athletes and hypertrophic cardiomyopathy patients. Journal of Electrocardiology, 2015, 48, 362-367.	0.9	16
69	A New Approach to Rare Diseases of Children: The Undiagnosed Diseases Network. Journal of Pediatrics, 2018, 196, 291-297.e2.	1.8	15
70	Systems biology of heart failure, challenges and hopes. Current Opinion in Cardiology, 2011, 26, 314-321.	1.8	14
71	Applying current normative data to prognosis in heart failure: The Fitness Registry and the Importance of Exercise National Database (FRIEND). International Journal of Cardiology, 2018, 263, 75-79.	1.7	14
72	Improving risk stratification in heart failure with preserved ejection fraction by combining two validated risk scores. Open Heart, 2019, 6, e000961.	2.3	13

#	Article	IF	Citations
73	Functional Cardiac Recovery and Hematologic Response to Chemotherapy in Patients With Light-Chain Amyloidosis (from the Stanford University Amyloidosis Registry). American Journal of Cardiology, 2017, 120, 1381-1386.	1.6	12
74	Findings From Cardiovascular Evaluation of National Collegiate Athletic Association Division I Collegiate Student-Athletes After Asymptomatic or Mildly Symptomatic SARS-CoV-2 Infection. Clinical Journal of Sport Medicine, 2022, 32, 103-107.	1.8	12
75	A toolkit for genetics providers in followâ€up of patients with nonâ€diagnostic exome sequencing. Journal of Genetic Counseling, 2019, 28, 213-228.	1.6	11
76	Value of Strain Imaging and Maximal Oxygen Consumption in Patients With Hypertrophic Cardiomyopathy. American Journal of Cardiology, 2017, 120, 1203-1208.	1.6	10
77	Defining genotype-phenotype relationships in patients with hypertrophic cardiomyopathy using cardiovascular magnetic resonance imaging. PLoS ONE, 2019, 14, e0217612.	2.5	10
78	Baseline Characteristics of the VANISH Cohort. Circulation: Heart Failure, 2019, 12, e006231.	3.9	10
79	â€œDoctors can read about it, they can know about it, but they've never lived with itâ€: How parents use social media throughout the diagnostic odyssey. Journal of Genetic Counseling, 2021, 30, 1707-1718.	1.6	10
80	Genomic Context Differs Between Human Dilated Cardiomyopathy and Hypertrophic Cardiomyopathy. Journal of the American Heart Association, 2021, 10, e019944.	3.7	9
81	TOWARDS TRANSCRIPTOMICS AS A PRIMARY TOOL FOR RARE DISEASE INVESTIGATION. Journal of Physical Education and Sports Management, 2022, , mcs.a006198.	1.2	9
82	Examining QRS amplitude criteria for electrocardiographic left ventricular hypertrophy in recommendations for screening criteria in athletes. Journal of Electrocardiology, 2015, 48, 368-372.	0.9	8
83	Exome sequencing identifies de novo pathogenic variants in FBN1 and TRPS1 in a patient with a complex connective tissue phenotype. Journal of Physical Education and Sports Management, 2017, 3, a001388.	1.2	8
84	Contractile reserve and cardiopulmonary exercise parameters in patients with dilated cardiomyopathy, the two dimensions of exercise testing. Echocardiography, 2017, 34, 1179-1186.	0.9	8
85	Mono- and Biallelic Protein-Truncating Variants in Alpha-Actinin 2 Cause Cardiomyopathy Through Distinct Mechanisms. Circulation Genomic and Precision Medicine, 2021, 14, CIRCGEN121003419.	3.6	8
86	The response to cardiac resynchronization therapy in <scp>LMNA</scp> cardiomyopathy. European Journal of Heart Failure, 2022, 24, 685-693.	7.1	7
87	The interaction of coronary tone and cardiac fibrosis. Current Atherosclerosis Reports, 2005, 7, 219-226.	4.8	6
88	Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 2015, 65, 570-572.	2.8	5
89	Genome Sequencing in HypertrophicÂCardiomyopathy. Journal of the American College of Cardiology, 2018, 72, 430-433.	2.8	5
90	Compound heterozygous KCTD7 variants in progressive myoclonus epilepsy. Journal of Neurogenetics, 2021, 35, 74-83.	1.4	4

#	Article	IF	Citations
91	Pharmacogenetics of Heart Failure: Evidence, Opportunities, and Challenges for Cardiovascular Pharmacogenomics. Journal of Cardiovascular Translational Research, 2008, 1, 25-36.	2.4	3
92	Extremely elevated lipoprotein(a), combined hyperlipidemia, and premature atherosclerosis in a Chinese family. Journal of Clinical Lipidology, 2010, 4, 543-547.	1.5	2
93	Repeats and Survival in Myotonic Dystrophy Type 1. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	2
94	Biallelic UBE4A loss-of-function variants cause intellectual disability and global developmental delay. Genetics in Medicine, 2021, 23, 661-668.	2.4	2
95	Cardiopulmonary Exercise Testing With Echocardiography to Assess Recovery in Patients With Ventricular Assist Devices. ASAIO Journal, 2021, Publish Ahead of Print, 1134-1138.	1.6	2
96	Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYH7 mutations. Stem Cell Research, 2021, 55, 102455.	0.7	2
97	Generation of three induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying TNNI3 mutations. Stem Cell Research, 2021, 57, 102597.	0.7	1
98	Letter by Wheeler et al Regarding Article, â€œRecognition and Significance of Pathological T-Wave Inversions in Athletesâ€• Circulation, 2015, 132, e180.	1.6	0
99	Multimodality Imaging for Risk Assessment of Inherited Cardiomyopathies. Current Cardiovascular Risk Reports, 2020, 14, 1.	2.0	0
100	Abstract 21307: Beta-Blockers Inferior to Calcium Channel Blockers in Hypertrophic Cardiomyopathy. Circulation, 2017, 136, .	1.6	0
101	Wnt Signaling Interactor WTIP (Wilms Tumor Interacting Protein) Underlies Novel Mechanism for Cardiac Hypertrophy. Circulation Genomic and Precision Medicine, 0, , .	3.6	0